These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 10182198

  • 1. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH, Goa KL.
    Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
    [Abstract] [Full Text] [Related]

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
    Encephale; 2005 Jul; 31(2):235-46. PubMed ID: 15959450
    [Abstract] [Full Text] [Related]

  • 3. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N, Foster RH, Olney R, Plosker GL.
    Drugs; 2001 Jul; 61(1):111-61. PubMed ID: 11217867
    [Abstract] [Full Text] [Related]

  • 4. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G, Heeg B, van Hout BA, Mehnert A.
    Pharmacoeconomics; 2005 Jul; 23 Suppl 1():49-61. PubMed ID: 16416761
    [Abstract] [Full Text] [Related]

  • 5. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH, Goa KL.
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [Abstract] [Full Text] [Related]

  • 6. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.
    Pharmacoeconomics; 2005 Jun; 23 Suppl 1():35-47. PubMed ID: 16416760
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
    Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ.
    Pharmacoeconomics; 2005 Jun; 23(3):299-314. PubMed ID: 15836010
    [Abstract] [Full Text] [Related]

  • 8. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.
    Pharmacoeconomics; 2005 Aug; 23 Suppl 1():75-89. PubMed ID: 16416763
    [Abstract] [Full Text] [Related]

  • 10. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P.
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [Abstract] [Full Text] [Related]

  • 11. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
    Achilla E, McCrone P.
    Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
    [Abstract] [Full Text] [Related]

  • 12. Impact of newer antipsychotics on outcomes in schizophrenia.
    Keks NA.
    Clin Ther; 1997 Apr; 19(1):148-58; discussion 126-7. PubMed ID: 9083717
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M, Mrhar A, Kos M.
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [Abstract] [Full Text] [Related]

  • 14. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
    Einarson TR, Vicente C, Zilbershtein R, Piwko C, Bø CN, Pudas H, Jensen R, Hemels ME.
    Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
    [Abstract] [Full Text] [Related]

  • 15. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
    Chue PS, Heeg B, Buskens E, van Hout BA.
    Pharmacoeconomics; 2005 Aug; 23 Suppl 1():62-74. PubMed ID: 16416762
    [Abstract] [Full Text] [Related]

  • 16. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M, Okamoto MP.
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [Abstract] [Full Text] [Related]

  • 17. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P.
    J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
    [Abstract] [Full Text] [Related]

  • 18. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM, Ereshefsky L.
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [Abstract] [Full Text] [Related]

  • 19. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.
    Value Health; 2004 Aug; 7(1):22-35. PubMed ID: 14720128
    [Abstract] [Full Text] [Related]

  • 20. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P.
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.